trending Market Intelligence /marketintelligence/en/news-insights/trending/Lvd65O6i5LKa4eWOL4d7lQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Novartis to acquire Ziarco Group to boost dermatology portfolio

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Novartis to acquire Ziarco Group to boost dermatology portfolio

Novartis AG agreed to acquire Ziarco Group Ltd., a privately held company focused on developments of novel treatments in dermatology, for an undisclosed sum.

The acquisition will add a once-daily oral H4 receptor antagonist in development for eczema to Novartis' dermatology portfolio and pipeline.

The transaction is subject to customary closing conditions, including regulatory approval.